Evidence map›Paper›PMID 39595059›Full record

ArticleBiomedicines2024

The Progression of Symptoms in Post COVID-19 Patients: A Multicentre, Prospective, Observational Cohort Study.

Merel E B Cornelissen, Myrthe M Haarman, Jos W R Twisk, Laura Houweling, Nadia Baalbaki, Brigitte Sondermeijer, Rosanne J H C G Beijers, Debbie Gach, Lizan D Bloemsma, Anke H Maitland-van der Zee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Merel E B CornelissenDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.ORCID 0009-0004-5707-4673
Myrthe M HaarmanDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Jos W R TwiskDepartment of Epidemiology and Data Science, Amsterdam University Medical Centers, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands.
Laura HouwelingDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.ORCID 0009-0004-9884-9738
Nadia BaalbakiDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Brigitte SondermeijerDepartment of Pulmonology, Spaarne Hospital, Spaarnepoort 1, 2134 TM Hoofddorp, The Netherlands.
Rosanne J H C G BeijersDepartment of Respiratory Medicine, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.ORCID 0000-0001-8192-0543
Debbie GachDepartment of Respiratory Medicine, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.
Lizan D BloemsmaDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Anke H Maitland-van der ZeeDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-0414-3442
P4O2 Consortium

Funding

Health Holland LSHM20104
6 · The paper itself

Abstract

backgroundAlthough the coronavirus disease 2019 (COVID-19) pandemic is no longer a public health emergency of international concern, 30% of COVID-19 patients still have long-term complaints. A better understanding of the progression of symptoms after COVID-19 is needed to reduce the burden of the post COVID-19 condition.

objectiveThis study aims to investigate the progression of symptoms, identify patterns of symptom progression, and assess their associations with patient characteristics.

methodsWithin the P4O2 COVID-19 study, patients aged 40-65 years were recruited from five Dutch hospitals. At 3-6 and 12-18 months post COVID-19, medical data were collected, and pulmonary function tests were performed. In between, symptoms were assessed monthly with a questionnaire. Latent class mixed modelling was used to identify symptom progression patterns over time, with multinomial logistic regression to examine associations with patient characteristics.

resultsEighty-eight patients (aged 54.4 years, 48.9% males) were included. Three trajectories were identified for fatigue and dyspnoea: decreasing, high persistent, and low persistent. The odds of "decreasing fatigue" was higher for never smokers and participants in the lifestyle intervention and lower for those having a comorbidity. The odds of "decreasing dyspnoea" was higher for moderate COVID-19 patients and lifestyle intervention participants and lower for males, mild COVID-19 patients, and those with a higher age.

conclusionsThree distinct trajectories were identified for fatigue and dyspnoea, delineating patterns of symptom persistence following COVID-19. Sex, age, smoking status, participation in lifestyle interventions and COVID-19 severity were associated with the likelihood of belonging to different trajectories. These findings highlight the heterogeneity of the long-term symptoms experienced by post COVID-19 patients and emphasise the importance of personalised treatment strategies.

Indexed as

dyspnoeafatiguepost COVID-19 conditionsymptom progressiontrajectories

Identifiers

PMID39595059
PMCPMC11591596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.